Connor, Clark & Lunn Investment Management (CC&L)’s Syndax Pharmaceuticals SNDX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,532	Closed	-$268K	–	1439
2022 Q4	$268K	Sell	10,532 -25,280	-71%	-$590K	﹤0.01%	995
2022 Q3	$861K	Buy	+35,812	New	+$803K	0.01%	689
2021 Q4	–	Sell	-11,530	Closed	-$220K	–	1188
2021 Q3	$220K	Buy	+11,530	New	+$192K	﹤0.01%	932

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s SNDX Position: Q1 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Syndax Pharmaceuticals (SNDX) in Q1 2023, closing a stake of 10,532 shares — an estimated $268K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in SNDX in Q3 2021 and held it in 3 quarters. The position peaked at $861K in Q3 2022. 163 funds tracked by Wall St. Rank hold SNDX as of Q1 2023.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Syndax Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 10,532 Syndax Pharmaceuticals shares in Q1 2023, an estimated $268K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Syndax Pharmaceuticals in Q3 2021 and held it in 3 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Syndax Pharmaceuticals position peaked at $861K in Q3 2022.
163 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2023, filed 10 May 2023.